NCT04455906Recruiting
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 111 (estimated)
- First submitted
- 29 Jun 2020
- Start date
- 30 Nov 2020
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Boston Children's Hospital
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT04455906
What you commit to
- Study type: Observational
- Planned participants: 111
- From 30 Nov 2020 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
- Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
- Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
- Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
Other illness
- Hypersensitivity to an agent used for the skin decolonization protocol
- History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
- Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
- Febrile illness at time of visits
- Suspected immune deficiency or family history of primary immunodeficiency
Other
- Enrollment in another clinical trial
- Phototherapy for AD within 4 weeks
- Bleach baths within 7 days of the first Visit
- Use of oral or topical antibiotics within 21 days of the beginning of the study
- Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
Who the study is looking for
- Male or female participants ≥6 to 65 yrs of age
- Meet AD Standard Diagnostic Criteria
Age in the registry: 6 years to 65 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boston Children's Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.